The healthcare sector (XLV) gained 4.91% in August, outperforming the S&P 500. Biotech led gains, with Moderna surging 156% on positive cancer vaccine trial results. Other top performers included Veeva Systems and Charles River Laboratories. Conversely, healthcare services and managed care faced pressure; DaVita was the top detractor, falling 26.7% due to dialysis business concerns and potential GLP-1 impact. Analysts note margin compression and payer mix shifts affecting laggards like CVS Health and UnitedHealth.
Healthcare August recap: Moderna jumps 156% as biotech shines; DaVita sinks
Login to unlock19characters for free
Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.